Tiburio Therapeutics
Cambridge, US · Founded 2018 · Delaware corporation · 4 known investors
Founders & leadership
JG
James G. McArthurExecutive
AN
Abraham N. CeesayExecutive
CM
Christoph M. AdamsNamed on SEC filing
Board
MK
Mette Kirstine AggerBoard director
DM
David MottBoard director
SA
Sandip AgarwalaBoard director
SN
Sara NayeemBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2018
▶$5MraisedJan 2019 · 5 investors · PharmaceuticalsRule 506(b)
▶$5MraisedJan 2019 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mette Kirstine AggerDirector
- David MottDirector
- Sandip AgarwalaDirector
- Sara NayeemDirector
- James G. McArthurExecutive Officer
- Christoph M. AdamsExecutive Officer, Director
- Abraham N. CeesayExecutive Officer
- Offering amount
- $31M
- Amount sold
- $5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Tiburio Therapeutics's investors?
- Tiburio Therapeutics's investors include Alexandria, Longitude Capital, Lundbeckfonden Ventures, New Enterprise Associates (NEA).
- How much funding has Tiburio Therapeutics raised?
- Tiburio Therapeutics has disclosed $5M raised across 1 round.
- Where is Tiburio Therapeutics headquartered?
- Tiburio Therapeutics is headquartered in Cambridge, US.